13D Filing: Golden Meditech Holdings Ltd and China Cord Blood Corp (NYSE:NYSE: CO)

Page 1 of 8

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Golden Meditech Stem Cells (BVI) Company Limited 78,874,106 0 78,874,106 0 78,874,106 65.40%
Golden Meditech Holdings Limited 78,874,106 0 78,874,106 0 78,874,106 65.40%
Bio Garden Inc 0 29,736,465 0 29,736,465 29,736,465 24.66%
Magnum Opus 0 25,761,155 0 25,761,155 25,761,155 21.36%
Yuen Kam 0 55,497,620 0 55,497,620 55,497,620 46.02%

Page 1 of 8 – SEC Filing









Washington, D.C. 20549









Under the Securities Exchange Act of 1934
(Amendment No.  26)


China Cord Blood Corporation

(Name of Issuer)


Ordinary Shares, par value $0.0001 per share

(Title of Class of Securities)



(CUSIP Number)


Yuen Kam

48th Floor, Bank of China Tower

1 Garden Road, Central

Hong Kong S.A.R.

(852) 3605-8180

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)


With a copy to:


Paul Strecker, Esq.

Shearman & Sterling

12th Floor, Gloucester Tower

The Landmark

15 Queens Road Central

Hong Kong

(852) 2978 8000


April 13, 2017

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box o.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


Follow Global Cord Blood Corp (NYSE:CO)

Page 1 of 8